Follow-up care of young childhood cancer survivors: attendance and parental involvement. by Vetsch, Janine et al.
 Follow-up care of young survivors 
Published in final edited form as: Support Care Cancer. 2016 Jul;24(7):3127-38. doi: 10.1007/s00520-016-3121-6 
1 
 
Follow-up care of young childhood cancer survivors: attendance and parental involvement 
 
Vetsch Janine (MSc)1, Rueegg S. Corina (PhD)1, Mader Luzius (MSc)1, Bergstraesser Eva (MD)2, Rischewski 
Johannes (MD)3, Kuehni Claudia (MD, MSc)4, Michel Gisela (PhD)1,4 
For the Swiss Paediatric Oncology Group* 
 
1Department of Health Sciences & Health Policy, University of Lucerne, Frohburgstrasse 3, 6002 Lucerne, Switzerland 
2Department of Oncology/Hematology, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland  
3Department of Oncology/Hematology, Children’s Hospital, Cantonal Hospital Lucerne, 6000 Lucerne, Switzerland 
4Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland  
 
*Swiss Paediatric Oncology Group (SPOG) Scientific Committee: Prof. Dr. med. R. Ammann, Bern; Dr. med. R. Angst, Aarau; 
Prof. Dr. med. M. Ansari, Geneva; PD Dr. med. M. Beck Popovic, Lausanne; Dr. med. P. Brazzola, Bellinzona; Dr. med. J. 
Greiner, St. Gallen; Prof. Dr. med. M. Grotzer, Zurich; Dr. med. H. Hengartner, St. Gallen; Prof. Dr. med. T. Kuehne, Basel; Bern; 
Prof. Dr. med. K. Leibundgut, Bern; Prof. Dr. med. F. Niggli, Zurich; Prof. Dr. med. N. von der Weid, Basel. 
 
Corresponding author: 
Gisela Michel, Department of Health Sciences and Health Policy, University of Lucerne 
Frohburgstrasse 3, 6002 Luzern, Switzerland 
Phone:+41 41 2295955, Fax: +41 41 2295635, E-mail: gisela.michel@unilu.ch 
 
Acknowledgements: We thank all parents of survivors for participating in our survey, the study team of the Swiss Childhood 
Cancer Survivor Study (Erika Brantschen Berclaz, Micòl Gianinazzi, Julia Koch, Fabienne Liechti), the data managers of the Swiss 
Paediatric Oncology Group (Claudia Anderegg, Nadine Beusch, Rosa-Emma Garcia, Franziska Hochreutener, Friedgard Julmy, 
Nadine Lanz, Heike Markiewicz, Genevieve Perrenoud, Annette Reinberger, Renate Siegenthaler, Verena Stahel, and Eva Maria 
Tinner), and the team of the Swiss Childhood Cancer Registry (Vera Mitter, Elisabeth Kiraly, Marlen Spring, Christina Krenger, 
Priska Wölfli). 
Financial support: This work was supported by the Swiss National Science Foundation (100019_153268/1; Ambizione grant 
PZ00P3_121682/1 and PZ00P3-141722 to GM). The Swiss Childhood Cancer Survivor Study was funded by the Swiss Cancer 
League (KLS-2215-02-2008, KFS-02631-08-2010, KLS-02783-02-2011). The work of the Swiss Childhood Cancer Registry is 
supported by the Swiss Paediatric Oncology Group (www.spog.ch), Schweizerische Konferenz der kantonalen 
Gesundheitsdirektorinnen und –direktoren (www.gdk-cds.ch), Swiss Cancer Research (www.krebsforschung.ch), Kinderkrebshilfe 
Schweiz (www.kinderkrebshilfe.ch), Ernst-Göhner Stiftung, Stiftung Domarena and National Institute of Cancer Epidemiology and 
Registration (www.nicer.ch). 
 
 
Citation: 
Vetsch, Janine; Rüegg, Corina Silvia; Mader, Luzius; Bergstraesser, Eva; Rischewski, 
Johannes; Kuehni, Claudia E; Michel, Gisela (2016). Follow-up care of young childhood cancer 
survivors: attendance and parental involvement. Supportive care in cancer, 24(7), S. 3127-3138. 
Springer 10.1007/s00520-016-3121-6 
 
  
 Follow-up care of young survivors 
Published in final edited form as: Support Care Cancer. 2016 Jul;24(7):3127-38. doi: 10.1007/s00520-016-3121-6 
2 
 
Follow-up care of young childhood cancer survivors: attendance and parental involvement 
 
Vetsch Janine (MSc)1, Rueegg S. Corina (PhD)1, Mader Luzius (MSc)1, Bergstraesser Eva (MD)2, Rischewski Johannes (MD)3, 
Kuehni Claudia (MD, MSc)4, Michel Gisela (PhD)1,4 
For the Swiss Paediatric Oncology Group* 
 
ABSTRACT 
 
Purpose: Despite recommendations, only a proportion of long-term childhood cancer survivors attend follow-up care. 
We aimed to 1) describe follow-up attendance of young survivors aged 11-17 years; 2) describe parental involvement 
in follow-up, and 3) investigate predictors of follow-up attendance and parental involvement. 
Methods: As part of the Swiss Childhood Cancer Survivor Study a follow-up questionnaire was sent to parents of 
childhood cancer survivors aged 11-17 years. We assessed follow-up attendance of the child, parents’ involvement in 
follow-up, illness perception (Brief IPQ) and socio-demographic data. Clinical data was available from the Swiss 
Childhood Cancer Registry.  
Results: Of 309 eligible parents 189 responded (67%; mean time since diagnosis 11.3 years, range 6.8-17.2) and 75% 
(n=141) reported that their child still attended follow-up. Of these, 83% (n=117) reported ≥1 visit per year and 17% 
(n=23) <1 visit every year. Most survivors saw pediatric oncologists (n=111; 79% of 141), followed by 
endocrinologists (n=24, 17%) and general practitioners (n=22, 16%). Most parents (92%) reported being involved in 
follow-up (n=130). In multivariable and Cox regression analyses, longer time since diagnosis (p=0.025) and lower 
perceived treatment control (assessed by IPQ4: how much parents thought follow-up can help with late effects; 
p=0.009) were associated with non-attendance. Higher perceived treatment control was the only factor associated 
(p=0.041) with parental involvement.  
Conclusion: Educating survivors and their parents on the importance and effectiveness of follow-up care might 
increase attendance in the longer term.  
 
Key words (4-6): parents of childhood cancer survivors; pediatric oncology; follow-up care; cohort study; 
questionnaire survey; young childhood cancer survivors 
 
INTRODUCTION 
Risk-based follow-up care is important for childhood 
cancer survivors to identify and treat late effects [1-3]. 
Due to their high risk for medical late effects such as 
cardiovascular or neurological complications and 
second malignancies, guidelines have been developed 
to provide recommendations for risk-stratified long-
term follow-up care [4-6]. These guidelines aimed to 
increase awareness of potential late effects, standardize 
follow-up across different medical specialists involved 
and increase follow-up attendance of survivors. Despite 
these recommendations only around 20-40% of 
adolescent and adult long-term survivors are in long-
term follow-up in Switzerland [7-9]. Factors associated 
with attendance were: younger age at study, older age 
at diagnosis and higher risk of treatment-related late 
effects [7]. Only one study from the US reported that 
young survivors between completion of treatment and 
5 years post-diagnosis were less likely to attend follow-
up if being male, having a brain tumor, longer time off 
treatment, and greater distance from hospital [10]. 
Parents play an important role in follow-up 
care of young survivors and are expected to be actively 
involved [11]. With children they are the caretakers and 
provide practical support, such as transportation to 
appointments. In addition, adult childhood cancer 
survivors are frequently accompanied by their mothers 
to follow-up visits. Reasons for this included concerns 
for health and well-being of their child, parental duty, 
personal interest and companionship [12]. Two studies 
showed that parents accompanied young adult 
survivors to follow-up care because of concerns about 
their child’s overall health and cancer recurrence [13, 
14]. We assume that parental involvement is influenced 
by their emotional state and how much they are affected 
by the illness. Follow-up care might provide an 
opportunity for parents to discuss their concerns and 
worries. However, there are no studies investigating 
follow-up attendance and parental involvement in 
follow-up care of young survivors of childhood cancer 
(aged below18 years) with regards to the opportunity of 
education to emphasize the importance of follow-up 
care.  
We aimed to 1) describe current follow-up 
care of young childhood cancer survivors (aged 11-17 
years) in Switzerland, including specialists visited and 
reasons for non-attendance; 2) describe parental 
involvement in follow-up care, and 3) investigate 
associations of follow-up attendance and parental 
involvement with clinical characteristics of the child, 
socio-demographic characteristics of parents and 
parents’ illness perception. 
METHODS 
Sample and procedure 
The Swiss Childhood Cancer Registry (SCCR) is a 
population-based registry including all cancer patients 
younger than 21 years and Swiss residents at diagnosis, 
who were diagnosed with leukemia, lymphoma, central 
nervous system (CNS) tumors, malignant solid tumors 
or Langerhans cell histiocytosis [15, 16]. The Swiss 
Childhood Cancer Survivor Study (SCCSS) is an 
ongoing, nationwide, long-term survey which includes 
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a baseline questionnaire (years 2007-2012) and a 
subsequent follow-up questionnaire (years 2010-2012).  
The baseline questionnaire included all patients 
registered in the SCCR who were diagnosed between 
1976-2005, aged below 16 years and having survived 
for at least 5 years [17]. Parents of survivors aged ≤15 
years completed the questionnaire for their children, 
whereas survivors 16+ years completed their own 
questionnaire. They received an initial information 
letter about the study from their former treating 
hospital. Ten days later they received a questionnaire 
with a prepaid return envelope. Non-responders were 
sent another questionnaire 4-6 weeks later. If they did 
not reply they were personally contacted by phone.  
The follow-up survey was performed 
approximately 1-3 years later. To collect the data 
reported in this paper a questionnaire was sent to all 
parents who had responded to the baseline 
questionnaire and whose child was aged 11-17 years at 
time of study (n=306; Supplemental Figure 1). The 
parent who had completed the baseline questionnaire 
was contacted again and received the questionnaire 
with a prepaid return envelope. Those who did not reply 
within two months, received a reminder with another 
questionnaire and prepaid return envelope. 
Questionnaires were available in German and French. 
Ethics approval was provided through the general 
cancer registry permission of the SCCR (The Swiss 
Federal Commission of Experts for Professional 
Secrecy in Medical Research). Additionally, we 
received a non-obstat statement from the ethics 
committee of the canton of Bern declaring that the 
ethics committee did not object to the conduct of the 
study. Participants gave implied informed consent for 
the study by returning the completed questionnaire. 
Measurements 
Outcomes assessed in the follow-up questionnaire 
Follow-up care attendance 
In Switzerland, childhood cancer survivors are 
regularly followed-up by their pediatric oncologist for 
10 years after diagnosis often into their early twenties, 
and are then usually discharged to a general practitioner 
(GP) or medical oncologist. Others may continue 
follow-up with their pediatric oncologist longer into 
adulthood. If discharged from pediatric oncology, 
further follow-up is poorly standardized. In younger 
survivors a parent usually attends follow-up 
appointments together with their child. However, as 
part of transition, most clinicians will have private 
appointments with the survivor only. We asked parents 
if their child still attended follow-up: 1) ‘yes, my child 
still attends regular follow-up appointments’; 2) ‘yes, 
my child still has irregular follow-up appointments’; 3) 
‘no, regular follow-up is completed, but my child goes 
to the doctor for any cancer-associated complications; 
4) ‘no, regular follow-up is completed and my child has 
not seen the doctor for a while’. For the analysis a 
binary variable was created: attenders (responses 1 or 
2) and non-attenders (responses 3 or 4).  
Parents of attenders were asked how frequently their 
child attends follow-up care (several times a year; once 
a year; every 2-3 years; every 4-5 years) and to indicate 
the health care provider on a list including: general 
practitioner, pediatric oncologist, adult oncologist, 
radiotherapist, gynecologist, psychologist, 
endocrinologist, and any other healthcare providers.  
Parents of survivors only seeing a doctor for cancer-
associated complications were asked which doctor they 
would visit in case of problems. The same list of 
specialists as described above was provided. Parents of 
survivors who had stopped attending follow-up seeing 
only a GP could give reasons why: ‘child was officially 
discharged ’, ‘child lives too far from a follow-up 
possibility’, ‘child is afraid that late effects could be 
detected’, ‘child doesn’t want to visit a children’s 
hospital’, ‘child thinks follow-up is unimportant’. 
Parents of non-attenders were asked the year of follow-
up completion. 
 
Parental involvement 
Parents were asked whether they are currently involved 
in follow-up care of their child: (yes/no). 
 
Explanatory variables assessed by questionnaire  
We assessed parents’ sex, age at study, migration 
background, language region, parents’ education and 
employment status. Parents’ age at study was divided 
in two categories ≤45 years and >45 years. Parents were 
classified as having a migration background if they 
were not Swiss citizens by birth or not born in 
Switzerland. Language region was divided into 
German and French. Parents’ education was divided 
into three categories: primary (compulsory schooling 
only); secondary (including vocational training, 
teachers, technical, commercial schools etc.); tertiary 
(including university) [18]. Employment status was 
coded as employed (yes/no).  
We also included an adapted version of the Brief Illness 
Perception Questionnaire (Brief IPQ) [19]. The Brief 
IPQ is a theoretically derived instrument providing 
information about components underlying the 
cognitive representation of the illness. We adapted the 
questions to parents of childhood cancer survivors as 
proposed in the manual of the IPQ. We wanted to assess 
how the former cancer disease and possible late effects 
still affect parents. Parents could express their 
accordance on an 11-point scale (0=absolutely not, 
10=absolutely) for the following items: cognitive 
illness representations: consequences (how much do 
the consequences of your child’s illness affect your 
life?), timeline (how long do you think the 
consequences of the child’s illness will continue?), 
personal control (how much control do you feel you 
have over the consequences of your child’s illness?), 
treatment control (how much do you think follow-up 
care can help with late effects of your child?), and 
identity (how often does your child experience 
symptoms from the illness consequences?); emotional 
representations: concerns (how concerned are you 
about your child’s illness?) and emotions (how much 
do the child’s illness consequences affect you 
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emotionally?); illness comprehensibility (how well do 
you feel you understand your child’s illness 
consequences?).  
From the baseline questionnaire of the SCCSS we 
extracted information about parent-reported late effects 
on the survivor (yes/no) [17].  
 
Clinical variables extracted from the Swiss Childhood 
Cancer Registry  
We extracted medical information on diagnosis and 
treatment of the child from the SCCR: cancer diagnosis, 
cancer treatment, type of treating hospital, age at study, 
time since diagnosis and relapse. We classified 
diagnosis according to the International Classification 
of Childhood Cancer (third edition) [20]. For analyses 
we grouped diagnoses into six major categories: 
leukemia, lymphoma, CNS tumors, neuroblastoma, 
bone/soft tissue sarcoma (STS) and other tumors. 
Treatment was coded as: surgery only, chemotherapy 
(without radiotherapy but may have had surgery), 
radiotherapy (may have had surgery and/or 
chemotherapy) and stem cell transplantation (SCT; 
may have had surgery and/or chemotherapy and/or 
radiotherapy). The type of treating hospital was divided 
into university hospital and regional hospital. Age at 
study was divided into: <14 years, 14-15 years and >15 
years. Time since diagnosis was divided into: 5-9 years, 
10-14 years and 15-17 years. Relapse was coded yes or 
no. 
Analyses 
All analyses were performed using Stata 13.1. We used 
descriptive statistics, chi-square statistics and t-tests to 
describe the study population, current follow-up care 
and parental involvement. We used univariable and 
multivariable logistic regression models to analyze 
associations of clinical characteristics, socio-
demographic characteristics and illness perception with 
follow-up attendance and parental involvement. The 
variables age at study, child’s age at study and time 
since diagnosis were centered around the mean for the 
regression analyses. In the multivariable model we 
included all variables that were statistically significant 
at p<0.05 in the univariable model. We used likelihood 
ratio tests to calculate p-values in the multivariable 
regression models. For the cumulative follow-up 
attendance analyses, follow-up time was calculated 
from date of diagnosis until date of follow-up 
completion or date of questionnaire completion if 
survivor was still in follow-up. Cox proportional 
hazards regression model was used to calculate 
cumulative follow-up attendance over time since 
diagnosis adjusted for age at study and time since 
diagnosis, and shown in a Kaplan-Meier estimation 
curve. 
 
RESULTS 
Of the 306 eligible parents, we traced and contacted 
284 (Supplemental Figure 2). Of those, 189 (67%) 
responded. The mean age of the parents was 46.1 years 
(SD 4.8, range 33.5-59.5 years), 
mean time since diagnosis 11.3 years (SD 2.5, range 
6.8-17.2) and mean age of the child at study completion 
was 14.7 years (SD 1.8, range 10.7-18.0 years; Table 
1). Most children were 
diagnosed with leukemia (39.2%), followed by CNS 
tumors (18.0%) and lymphomas (8.5%). Participating 
and non-participating parents were similar regarding 
language region of Switzerland, cancer type, treatment 
received, type of treating hospital, child's age at 
diagnosis, time since diagnosis, relapse status and 
parent-reported late effects. 
Follow-up care attendance 
Most parents (n=141, 74.6%) reported that their child 
still attended follow-up either regularly (n=117, 61.9%) 
or irregularly (n=24, 12.7%; Figure 1). Specialists 
most often seen for follow-up care were: pediatric 
oncologists (n=111/141, 78.7%), endocrinologists 
(n=24/141, 17.0%) and general practitioners 
(n=22/141, 15.6%).  
Among non-attenders, 11 (23%) reported that they only 
ever see a doctor when a complication has occurred and 
37 (77%) reported that they had completed follow-up 
care. Among those seeing a doctor only for cancer-
associated complications eight (72.7% ) reported 
visiting a general practitioner and three (27.3%) a 
pediatric oncologist. Parents of children who 
completed follow-up gave the following reasons: child 
was officially discharged (n=33, 89.2%), child thinks 
follow-up care is unimportant (n=3, 8.1%) and child 
does not want to visit a children’s hospital (n=1, 2.7%). 
Parental involvement in follow-up care 
Most parents reported that they were involved in 
follow-up care (n=130, 92.2% of 141).  
Factors associated with non-attendance 
We compared associations between not attending / 
attending follow-up and clinical, socio-demographic 
variables and parents’ illness perception. In the 
univariable and Cox regression, non-attenders were 
older than attenders (OR 1.50, Confidence Interval (CI) 
1.22-1.85p=0.001; Table 2) and diagnosed a longer 
time ago (OR 1.34, CI 1.16-1.55; p=0.001; Figure 2). 
Regular visits were reported more frequently in 
younger age groups (Figure 1). Parents of non-
attenders reported lower treatment control (they did not 
think that follow-up could help with late effects; IPQ 
item 4, OR 0.86, CI 0.79-0.96, p=0.005). In the 
multivariable regression older age at study (OR 1.32, 
CI 1.03-1.69, p=0.024), longer time since diagnosis 
(OR 1.20, CI 1.01-1.42, p=0.033) and lower perceived 
treatment control (OR 0.86, CI 0.77-0.96, p=0.001) 
remained associated with non-attendance.  
Non-attenders who were officially discharged and non-
attenders with other reasons were similar in socio-
demographic characteristics and clinical factors. The 
only difference was that those who were officially 
discharged were more likely to be older (p=0.040; data 
not shown) and had parents with lower perceived 
treatment control (p=0.041). 
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Factors associated with parental involvement 
Parental involvement in follow-up care was associated 
with higher perceived treatment control (follow-up can 
help with late effects; IPQ item 4, OR 1.14, CI 1.02-
1.27, p=0.020; Table 3), increased identity (the child 
experiences symptoms as a consequence from the 
illness; IPQ item 5, OR 1.26, CI 1.06-1.49, p=0.008), 
increased concerns about the consequences of the 
illness (IPQ item 6, OR 1.17, CI 1.05-1.32, p=0.004) 
and increased emotions (emotionally more affected by 
consequences of the treatment; IPQ item 8, OR 1.17, CI 
1.03-1.34, p=0.011). Parental involvement was not 
significantly associated with socio-demographic and 
clinical characteristics. In the multivariable model only 
perceived treatment control remained associated (OR 
1.13, CI 1.01-1.28, p=0.041). 
 
DISCUSSION 
This is one of the first studies looking at follow-up 
attendance and parental involvement in young 
survivors of childhood cancer. We found that three out 
of four 11-17 year old survivors still attended follow-
up care, however, the number decreased with age such 
that only half of the survivors aged 15 years or older 
still attended follow-up care. The specialists most often 
visited were pediatric oncologists followed by 
endocrinologists and general practitioners. As 
expected, attendance decreased with longer time since 
diagnosis and increasing age of survivor. The majority 
of parents reported that they were involved in follow-
up care of their child. Parents of non-attenders reported 
lower treatment control (follow-up can help with late 
effects) whereas parents involved in follow-up were 
more likely to report greater treatment control. 
 
Survivors diagnosed a longer time ago and who were 
older at the time of study were less likely to attend 
follow-up. This is in line with other studies which 
focused on young survivors [10] or on adolescent or 
adult survivors [7-9, 21, 22]. This can be hazardous 
because the likelihood of late effects and second 
malignancies increases with time since diagnosis [3]. 
Even 45 years after diagnosis survivors were at higher 
risk of premature death due to second cancers or severe 
cardiac or respiratory events [23]. Therefore lifelong 
follow-up care is often recommended [24]. However 
follow-up care in Switzerland is usually organized by 
pediatric oncologist and older survivors have to take 
over the responsibility for their follow-up care. They 
are more prone to get lost to follow-up when no regular 
follow-up at an adult specialist or general practitioner 
is organized. However, survivors in our sample were 
still in the age group in which follow-up at the pediatric 
oncologist is usually provided. Parents of non-attenders 
indicated lower treatment control indicating that they 
were probably unaware of the importance of follow-up 
care. These findings are in line with other studies 
showing that lack of knowledge might prevent 
survivors from seeking and receiving long-term 
medical or psychosocial follow-up care [7, 25-27]. To 
enhance care they suggested self-advocacy training for 
survivors and primary care physicians [26]. We showed 
in a previous study, including the same sample, that 
many parents had information needs especially on the 
domains follow-up care and late effects [28]. We 
assume that parents receiving the desired information 
would be more likely to understand the importance of 
follow-up care and motivate their child to stay in 
follow-up. A future study should investigate whether 
providing tailored additional information, preferably in 
written format, would increase attendance of young 
survivors. Results from the US showed that parents 
with a low perceived likelihood of their child 
developing late effects did not try to seek more 
information and were unlikely to attend follow-up [29]. 
We found no associations with any socio-demographic 
or clinical variables, which was in line with another 
study [13]. In contrast to other studies, which showed 
that follow-up attendance increased with severity of 
late effects [8], we found no difference by cancer 
diagnosis, parent-reported late effects or relapse even 
though risk-adapted follow-up care were indicated. 
 
Among young children, parental involvement at 
medical visits is expected. In a recent study, mothers 
reported that the most important reason was concern for 
child’s health and well-being. [12]. They also reported 
that it is a parental duty to accompany and support their 
child. This duty is of great importance in the younger 
age group where parents together with health care 
providers are responsible to motivate the child to stay 
in follow-up. In addition they help their child to become 
aware of their former disease and teach them the 
importance of early screening and detection of late 
effects. Parents were more likely to be involved if they 
thought follow-up care could help with late effects 
(treatment control) indicating that parents’ 
understanding of the disease and being aware of the 
importance of follow-up led to greater involvement.  
A qualitative study from England suggested that 
parental involvement is not only important for young 
survivors but also for older age groups; [30] other 
studies showed that parents remained involved in adult 
care because they remained concerned about cancer 
recurrence and overall health [13, 14]. Parental 
involvement was also reported to be very important in 
other chronic disease states. A study in children with 
diabetes showed that parental involvement was 
associated with improved maintenance and treatment 
adherence in disease management [31]. A different 
study in early obesity treatment showed that parental 
involvement was significantly higher in those who lost 
weight [32].  
 
A limitation of this study is selection bias because 
parents of specific groups may have been more 
reluctant to complete the questionnaire; others may 
have been excluded because they did not complete the 
baseline questionnaire. Additionally, we only contacted 
one parent, mostly mothers, and thus information about 
involvement of the other parent is lacking. Also details 
about parental involvement in follow-up care were 
lacking. This also explains the large difference in 
numbers of male and female participants. Another 
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limitation is self-reporting bias: parents might have 
forgotten the frequency of appointments or did not 
correctly recall the information and with the lack of 
medical record review we could not verify if children 
were officially discharged. The small sample size 
resulted in reduced accuracy for estimating effect sizes 
and therefore in large 95% confidence intervals. 
Therefore, only limited stratification of results was 
possible and only a few variables could be included in 
the final multivariable models. 
A major strength is the population-based sample of 
parents of childhood cancer survivors with 
prospectively collected data on the clinical variables of 
their children from the SCCR and data available from 
the follow-up questionnaire from the SCCSS. The 
response rate was good (67%).  
 
To improve follow-up attendance and parents’ support 
of children, parents’ beliefs should be strengthened 
through contact with other survivors and parents or 
health care professionals, emphasizing the importance 
of follow-up care. This might be especially important 
during and after transition to adult care. Researchers 
together with health care providers should organize 
regular meetings updating parents and survivors about 
potential late effects and give them the opportunity to 
meet and exchange their experiences. Each survivor 
and parents of young survivors should receive a 
personal passport for care and/or specific brochures 
detailing recommendations of ongoing screening. Such 
a passport was shown to be effective in survivors to 
improve knowledge of late effects and to see the 
benefits of long-term follow-up. [33-35]. Additionally, 
transition to adult care should be improved and more 
uniformly organized. Only if parents and survivors 
have the knowledge about effectiveness of follow-up 
care and are given adequate information throughout the 
cancer trajectory, will survivors reaching adulthood be 
able to take over responsibility of their own health and 
attend follow-up care visits independently even a long 
time after treatment has ended [7, 9, 36]. 
Longer duration since diagnosis is associated with 
lower follow-up attendance, and most parents who 
believed follow-up can help with late effects are 
involved in follow-up visits. Educating survivors and 
their parents on the importance and effectiveness of 
follow-up care might increase attendance in the longer 
term.  
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Table 1. Characteristics of the study population, comparing participating parents and non-
participating parents 
 
   Participating parents Non-participating parentsa 
  N %c N % c 
Total 189 100 117 100 
Socio-demographic characteristics of parents  
Sex     
  Female 160 84.7 n.a.d 
n.a. 
 
  Male 29 15.3  
Migration background    
  Swiss 173 91.5 n.a.  
  Migration background 16 8.5 n.a.  
Language region     
  German 132 70.2 78 66.7 
  French  56 29.8 39 33.3 
Education      
  Primary  101 54.3 n.a.  
  Secondary 62 33.3 n.a.  
  Tertiary 23 12.4 n.a.  
Employment      
  Employed 150 79.4 n.a.  
  Unemployed 39 20.6 n.a.  
Clinical characteristics of the child    
Diagnosis     
  Leukemias 74 39.2 46 39.3 
  Lymphomas 16 8.5 10 8.5 
  CNS tumors 34 18.0 23 19.7 
  Neuroblastoma 13 6.9 8 6.8 
  Retinoblastoma 13 6.9 5 4.3 
  Renal tumors 12 6.3 8 6.8 
  Hepatic tumors 4 2.1 3 2.6 
  Malignant tumors 2 1.1 3 2.6 
  Soft tissue sarcomas 14 7.4 3 2.6 
  Germ cell tumors 2 1.1 3 2.6 
  LCH 2 1.1 3 2.6 
  Othere 3 1.6 0 0.0 
Treatment receivedf     
  Surgery only 30 16.0 20 17.5 
  Chemotherapy 118 63.1 74 64.9 
  Radiotherapy 30 16.0 17 14.9 
  SCT 9 4.9 3 2.6 
Type of treating hospital    
  University hospital 160 84.7 102 87.2 
  Regional hospital 29 15.3 15 12.8 
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Table 1 contd. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note Percentages are based upon available data for each variable. Abbreviations: CNS, Central Nervous System; 
LCH, Langerhans Cell Histiocytosis; SCT, Stem Cell Transplantation; SD, Standard Deviation; IPQ, Illness 
Perception Questionnaire; aNon-participants include: parents who did not respond (n=92), with unknown address 
(n=22) or who refused to participate (n=3) (Supplemental Figure 2); cColumn percentages are given; dinformation was 
not available from non-participants; eOther: ICCC-3;malignant epithelial neoplasms, malignant melanomas and other 
or unspecified malignant neoplasms; fChemotherapy may include surgery, radiotherapy may include chemotherapy 
and/or surgery. 
 
 
  
 Participating parents Non-participating parentsa 
 N %c N % c 
Total 189 100 117 100 
Relapse      
  No  168 88.9 104 88.9 
  Yes 21 11.1 13 11.1 
Parent-reported late effects    
  No  100 54.4 68 64.2 
  Yes 84 45.6 38 35.8 
 Participants Non-participantsa 
 Mean SD Mean SD 
Parent’s age 46.1 4.8 n.a. n.a. 
Child’s age at study 14.7 1.8 15.0 1.9 
Child’s age at diagnosis 3.4 2.2 3.6 2.4 
Time since diagnosis 11.3 2.5 11.4 2.5 
IPQ1: Consequences 3.1 2.9 n.a. n.a. 
IPQ2: Timeline 5.2 4.1 n.a. n.a. 
IPQ3: Personal control 3.5 2.9 n.a. n.a. 
IPQ4: Treatment control 6.6 3.4 n.a. n.a. 
IPQ5: Identity 2.4 2.9 n.a. n.a. 
IPQ6: Concern 5.4 3.3 n.a. n.a. 
IPQ7: Illness 
comprehensibility 
7.6 2.6 n.a. n.a. 
IPQ8: Emotions 5.0 3.0 n.a. n.a. 
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Table 2. Factors associated with follow-up non-attendance (from univariable and 
multivariable logistic regression models) 
 
 Non-
attenders Univariable regression  Multivariable regressiond 
           
 N Total N %a OR 95%CI p OR 95%CI pe 
Socio-demographic characteristics of parents     
Sex      0.234    
 Female 160 38 23.8 1      
 Male 29 10 34.5 1.69 0.72-3.95     
Migration background     0.185    
 Swiss 173 46 26.6 1      
 Immigrant 16 2 12.5 0.39 0.09-1.80     
Language region      0.091    
 German 132 29 22.0 1      
 French 56 19 33.9 1.82 0.92-3.63     
Education      0.329    
 Primary 101 26 25.7 1      
 Secondary 62 17 27.4 1.09 0.53-2.22     
 Tertiary 23 3 13.0 0.43 0.12-1.58     
Employment      0.654    
 Employed 150 37 24.7 1      
 Unemployed 39 11 28.2 1.19 0.54-2.64     
Clinical characteristics of the child       
Diagnosis      0.446    
 Leukemia 74 57 77.0 1      
 Lymphoma 16 10 62.5 2.01 0.64-6.34     
 CNS tumor 34 28 82.4 0.72 0.26-2.02     
 Neuroblastoma 13 8 61.5 2.1 0.61-7.25     
 Bone tumor/STS 16 13 81.3 0.78 0.2-3.04     
 Other tumorb 24 16 66.7 1.68 0.17-0.51     
Treatment receivedc      0.071    
 Surgery 30 10 33.3 1      
 Chemotherapy 118 33 27.9 0.78 0.33-1.83     
 Radiotherapy 30 3 10.0 0.22 0.05-0.91     
 SCT 9 1 11.1 0.25 0.03-2.29     
Type of treating hospital     n.a.    
 University hospital 160 48 30.0       
 Regional hospital 29 0 0.0 n.a. n.a.     
Relapse      0.466    
 No 168 44 26.2 1      
 Yes 21 4 19.1 0.66 0.21-2.08     
Parent-reported late effects     0.185    
 No 100 30 30.0 1      
 Yes 84 18 21.4 0.64 0.32-1.25     
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Table 2 contd. 
 
 
Note Percentages are based upon available data for each variable. Abbreviations: CI, Confidence Interval; CNS, 
Central Nervous System; OR, Odds Ratio; SCT, Stem Cell Transplantation; aRow percentages are given; bOther: 
malignant epithelial neoplasms, malignant melanomas and other or unspecified malignant neoplasms; cChemotherapy 
may include surgery, radiotherapy may include chemotherapy and/or surgery; dAll variables that were statistically 
significant in the univariable model on a significance level of p<0.05 were included; ep-value calculated with 
likelihood ratio test. 
 
  
 
 
 Non-
attenders Univariable regression Multivariable regressiond 
 N Total Mean SD OR 95%CI p OR 95%CI pe 
Age at study (years) 181 46.79 5.16 1.04 0.97-1.20 0.240    
Child’s age at study 
(years) 189 15.72 1.71 1.50 1.22-1.85 0.001 
1.32 1.03-1.69 0.024 
Time since diagnosis 
(years) 189 12.57 2.22 1.34 1.16-1.55 0.001 
1.20 1.01-1.42 0.033 
IPQ1: Consequences 185 3.05 2.95 0.96 0.86-1.08 0.551    
IPQ2: Timeline 182 5.21 4.13 0.97 0.89-1.06 0.573    
IPQ3: Personal control 177 3.50 2.89 0.99 0.88-1.12 0.885    
IPQ4: Treatment control 182 6.64 3.40 0.86 0.79-0.96 0.005 0.86 0.77-0.96 0.001 
IPQ5: Identity 183 2.44 2.87 0.88 0.78-1.02 0.063    
IPQ6: Concern 187 5.35 3.34 0.96 0.87-1.05 0.368    
IPQ7: Illness 
comprehensibility 184 7.58 3.05 0.92 0.81-1.04 0.198    
IPQ8: Emotions 183 5.02 3.05 0.95 0.86-1.07 0.465    
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Table 3. Factors associated with parental involvement in follow-up care (from univariable 
and multivariable logistic regression models) 
 
 
 
 
 
Table 3 contd. 
 
 Parental 
involvement Univariable regression  Multivariable regressione 
           
 N Total N (%)a OR 95%CI p OR 95%CI pf 
Socio-demographic characteristics of parent responder     
Sex      0.129    
 Female 157 126 80.3 1      
 Male 27 18 66.7 0.49 0.21-1.19     
Migration background     0.321    
 Swiss 168 130 77.4 1      
 Immigrant 16 14 87.5 2.05 0.45-9.40     
Language region      0.199    
 German 127 96 75.6 1      
 French 56 47 83.9 1.69 0.74-3.83     
Education      0.970    
 Primary 99 79 79.8 1      
 Secondary 60 47 78.3 0.92 0.42-2.01     
 Tertiary 23 18 78.3 0.91 0.30-2.75     
Employment      0.673    
 Employed 147 116 78.9 1      
 Unemployed 37 28 75.7 0.83 0.36-1.94     
Clinical characteristics of the child       
Diagnosis      0.486    
 Leukemia 72 14 19.4 1      
 Lymphoma 16 6 37.5 0.41 0.13-1.29     
 CNS tumor 34 6 17.7 1.12 0.39-3.24     
 Neuroblastoma 12 2 16.7 1.21 0.24-6.14     
 Bone tumor/STS 15 2 13.3 1.57 0.32-7.76     
 Other tumorb 23 7 30.4 0.55 0.19-1.60     
Treatment receivedc      0.345    
 Surgery 29 21 72.4 1      
 Chemotherapy 114 87 76.3 1.23 0.49-3.09     
 Radiotherapy 30 26 86.7 2.48 0.65-9.37     
 SCT 9 9 100.0 n.a.d n.a.     
Type of treating hospital     0.101    
 University hospital 156 119 76.3 1      
 Regional hospital 28 25 89.3 2.59 0.74-9.07     
Relapse      0.118    
 No 163 125 76.7 1      
 Yes 21 19 90.5 2.89 0.64-12.96     
Parent-reported late effects     0.099    
 No 96 70 72.9 1      
 Yes 83 69 83.1 1.83 0.88-3.79     
Parents’ overall information needs   0.002   0.138 
 No 10 3 30.0 1   1   
 Yes 122 95 77.9 8.21 1.99-33.91  3.32 0.84-1.36  
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Note Percentages are based upon available data for each variable. Abbreviations: CI, Confidence Interval; CNS, 
Central Nervous System; OR, Odds ratio; SCT, Stem Cell Transplantation; aRow percentages are given; bOther: 
malignant epithelial neoplasms, malignant melanomas and other or unspecified malignant neoplasms; cChemotherapy 
may include surgery, radiotherapy may include chemotherapy and/or surgery; dsuccess perfectly predicted; eAll 
variables that were statistically significant in the univariable model on a significance level of p<0.05 were included; 
fp-value calculated with likelihood ratio test. 
  
 
 
 
 
 
Univariable regression Multivariable regressione 
 N Total Mean SD OR 95%CI p OR 95%CI pf 
Age at study (years) 181 45.77 4.57 0.99 0.86-1.15 0.896    
Child’s age at study 
(years) 189 14.51 1.77 1.06 0.73-1.52 0.760 
   
Time since diagnosis 
(years) 189 10.91 2.46 1.17 0.88-1.57 0.266  
  
IPQ1: Consequences 185 3.05 2.95 1.11 0.97-1.26 0.112    
IPQ2: Timeline 182 5.21 4.13 1.06 0.97-1.17 0.156    
IPQ3: Personal control 184 3.49 2.89 1.06 0.93-1.22 0.382    
IPQ4: Treatment control 182 6.63 3.35 1.14 1.02-1.27 0.020 1.07 0.84-1.36 0.577 
IPQ5: Identity 183 2.43 2.86 1.26 1.06-1.49 0.008 1.54 0.83-2.87 0.093 
IPQ6: Concern 187 5.35 3.34 1.17 1.05-1.32 0.004 1.15 0.85-1.57 0.354 
IPQ7: Illness 
comprehensibility 184 7.58 2.57 1.04 0.91-1.19 0.547    
IPQ8: Emotions 183 5.02 3.04 1.17 1.03-1.34 0.011 1.00 0.70-1.40 0.960 
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Figure 1. Follow-up attendance of young childhood cancer survivors 
Figure 1 shows the overall proportion of childhood cancer survivors attending and not attending 
follow-up care stratified by child’s age at study 
Legend: Regular visit: 1) ‘yes, my child still attends regular follow-up appointments’; Irregular 
visit: 2) ‘yes, my child still has irregular follow-up appointments’; Seeing a doctor when 
experiencing complications: 3) ‘no, regular follow-up is completed, but my child goes to the 
treating doctor when having cancer-associated complications; discharged: 4) ‘no, regular follow-
up is completed and my child has not seen the treating doctor for a while’ 
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Figure 2. Follow-up attendance calculated from Kaplan-Meier estimation stratified by child’s age 
at diagnosis 
Figure 2 shows the probability of follow-up attendance over time since diagnosis (years) stratified 
by the child’s age at diagnosis: 0-1 years, 2-4 years, 5+ years 
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Supplemental Figure 1: Different data sources of the variables used in the present study 
Supplemental figure 1 shows the data sources and the variables used in the present study 
 
 
 
 
Supplemental Figure 2: Participants and response rate of parents in the Swiss Childhood Cancer 
Survivor Study follow-up questionnaire 
Supplemental figure 2 shows the flow diagram of our study population starting from those parents 
eligible for the study to those included in the analysis. 
 Parents eligible for the follow-up questionnaire 
(n=306) 
No current address available (n=22; 7.2% of 
Did not respond (n=92; 32.0%) 
Traced and sent a questionnaire (n=284; 
 
Refused to participate (n=3; 1.0%) 
Returned a full questionnaire (n=189; 67%) and 
    
